Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to $4.1 million.

  • Tandem Diabetes Care's Capital Expenditures fell 2189.35% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year decrease of 2354.29%. This contributed to the annual value of $19.2 million for FY2024, which is 2825.32% down from last year.
  • As of Q3 2025, Tandem Diabetes Care's Capital Expenditures stood at $4.1 million, which was down 2189.35% from $5.0 million recorded in Q2 2025.
  • Tandem Diabetes Care's Capital Expenditures' 5-year high stood at $13.7 million during Q3 2022, with a 5-year trough of $1.8 million in Q2 2021.
  • Its 5-year average for Capital Expenditures is $5.7 million, with a median of $5.2 million in 2023.
  • In the last 5 years, Tandem Diabetes Care's Capital Expenditures crashed by 8145.31% in 2021 and then skyrocketed by 56760.33% in 2022.
  • Over the past 5 years, Tandem Diabetes Care's Capital Expenditures (Quarter) stood at $5.7 million in 2021, then dropped by 2.07% to $5.6 million in 2022, then fell by 7.61% to $5.2 million in 2023, then crashed by 40.97% to $3.1 million in 2024, then surged by 33.33% to $4.1 million in 2025.
  • Its Capital Expenditures stands at $4.1 million for Q3 2025, versus $5.0 million for Q2 2025 and $4.2 million for Q1 2025.